New Street analysts set a $12 price target for Aquestive Therapeutics, implying 193% upside, after its stock jumped 38.98% following the FDA’s Complete Response Letter for Anaphylm. The FDA flagged human factors deficiencies in Anaphylm’s packaging and labeling, prompting redesigned pouches and new human factors and PK studies.